Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Long Term DebtTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abivax (ABVX) Total Current Liabilities: 2021-2024

Historic Total Current Liabilities for Abivax (ABVX) over the last 4 years, with Dec 2024 value amounting to $100.4 million.

  • Abivax's Total Current Liabilities rose 47.68% to $127.2 million in Q2 2025 from the same period last year, while for Jun 2025 it was $127.2 million, marking a year-over-year increase of 47.68%. This contributed to the annual value of $100.4 million for FY2024, which is 2.94% up from last year.
  • Latest data reveals that Abivax reported Total Current Liabilities of $100.4 million as of FY2024, which was up 2.94% from $97.6 million recorded in FY2023.
  • Over the past 5 years, Abivax's Total Current Liabilities peaked at $100.4 million during FY2024, and registered a low of $38.2 million during FY2021.
  • Over the past 3 years, Abivax's median Total Current Liabilities value was $97.6 million (recorded in 2023), while the average stood at $84.1 million.
  • Data for Abivax's Total Current Liabilities shows a peak YoY skyrocketed of 79.91% (in 2023) over the last 5 years.
  • Yearly analysis of 4 years shows Abivax's Total Current Liabilities stood at $38.2 million in 2021, then soared by 42.06% to $54.2 million in 2022, then skyrocketed by 79.91% to $97.6 million in 2023, then grew by 2.94% to $100.4 million in 2024.